Key features and details | |
Cat. No. | MABL-1862 |
Name | Anti-HLA-DR mAbs |
Clone No. | AFD- HD8 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | immunotherapy, WB, FC |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody specifically binds an epitope comprising amino acids 61-WNSQKDILEQARA-73 in the beta chain of human HLA-DR. This antibody can recognize most polymorphic forms of the human HLA- DR. This antibody can recognize 99.2% of HLA-DRB alleles and also is capable of cross reacting with HLA-DP alleles some HLA-DQ alleles. HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. HLA-DR is also involved in several autoimmune conditions, disease susceptibility and disease resistance. |
Alternative Name | CD74; Beta chain HLA-DR; HLA-DR β-chain; β-chain; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33 |
UniProt | P04233 |
Immunogen | The original antibody was generated by immunizing a human transgenic KM mice with HLA- DR-expressing L929 cells. |
Application Notes | The binding specificity of this antibody to HLA-DR-positive B-lymphoblastoid cell line, SKW6.4 was tested using western blot. The reactivity of this antibody towards various HLA-DR positive cell lines like ARH77, Daudi, Granta519, IM-9, MC/CAR, Raji, RPMI1788, HS-Sultan, Namalwa, RL, Ramos, SKW6.4 etc. was determined using Alexa488 labelled antibody by flow cytometry. This antibody is reported to exert strong antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and significantly extended the life span of immunocompromised mice inoculated with non-Hodgkin lymphoma cell lines. This antibody has potential applications in HLA-DR targeted immunotherapy as it is likely to evoke similarly strong responses in individuals carrying different HLA-DR alleles (PMID: 17428256). |
Antibody First Published | Tawara et al. Fully human antibody exhibits pan-human leukocyte antigen- DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Cancer Sci. 2007 Jun;98(6):921-8. PMID:17428256 |
Note on publication | Describes the generation and characterization of this antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
